Enliven Therapeutics jumped on strong ELVN-001 phase 1b CML data, but a rich valuation may cap upside. Click here to read an ...
Enliven Therapeutics' stock rose after early trial results showed strong responses and good safety for its leukemia drug, ...
BOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small ...
InvestorsHub on MSN
Enliven shares advance on encouraging early data from CML treatment study
Shares of Enliven Therapeutics (NASDAQ:ELVN) climbed 7% on Thursday after the company released positive early results from a ...
Investors might want to bet on Enliven Therapeutics, Inc. (ELVN), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
BOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of ...
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...
Enliven Therapeutics (EVN) stock jumps as the company post initial early-stage trial data for its lead asset ELVN-001 in ...
Investors in Enliven Therapeutics Inc (Symbol: ELVN) saw new options begin trading this week, for the February 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback